Analysts Set $255.00 Price Target for Mesa Laboratories, Inc. (MLAB)

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price objective of $255.00 for the company and are predicting that the company will post $2.13 earnings per share for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 105 out of 256 based on the ratings given to its competitors.

Several equities analysts have commented on the company. ValuEngine raised Mesa Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. BidaskClub upgraded Mesa Laboratories from a “strong sell” rating to a “sell” rating in a research note on Friday, May 3rd. Zacks Investment Research upgraded Mesa Laboratories from a “hold” rating to a “buy” rating and set a $257.00 price objective on the stock in a research note on Friday, February 8th. TheStreet upgraded Mesa Laboratories from a “c” rating to a “b-” rating in a research note on Friday, February 8th. Finally, Sidoti assumed coverage on Mesa Laboratories in a research note on Wednesday, March 13th. They issued a “neutral” rating on the stock.

Mesa Laboratories stock traded up $7.02 during trading hours on Monday, hitting $254.30. The stock had a trading volume of 1,836 shares, compared to its average volume of 28,475. The company has a quick ratio of 1.20, a current ratio of 1.57 and a debt-to-equity ratio of 0.25. The stock has a market cap of $957.56 million, a price-to-earnings ratio of 40.97 and a beta of 0.37. Mesa Laboratories has a fifty-two week low of $156.99 and a fifty-two week high of $263.27.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 31st will be paid a $0.16 dividend. The ex-dividend date of this dividend is Thursday, May 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.25%. Mesa Laboratories’s dividend payout ratio is currently 10.36%.

In other news, Director Robert V. Dwyer sold 5,575 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $232.00, for a total value of $1,293,400.00. Following the sale, the director now directly owns 53,913 shares in the company, valued at approximately $12,507,816. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David M. Kelly sold 684 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $230.00, for a total value of $157,320.00. Following the completion of the sale, the director now owns 3,584 shares in the company, valued at $824,320. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,005 shares of company stock worth $1,856,333. Corporate insiders own 15.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC grew its position in Mesa Laboratories by 2.3% during the 4th quarter. Conestoga Capital Advisors LLC now owns 486,256 shares of the medical instruments supplier’s stock worth $101,331,000 after acquiring an additional 10,817 shares during the last quarter. BlackRock Inc. grew its position in Mesa Laboratories by 10.2% during the 4th quarter. BlackRock Inc. now owns 252,580 shares of the medical instruments supplier’s stock worth $52,634,000 after acquiring an additional 23,384 shares during the last quarter. Vanguard Group Inc grew its position in Mesa Laboratories by 2.1% during the 3rd quarter. Vanguard Group Inc now owns 161,627 shares of the medical instruments supplier’s stock worth $30,000,000 after acquiring an additional 3,309 shares during the last quarter. Vanguard Group Inc. grew its position in Mesa Laboratories by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 161,627 shares of the medical instruments supplier’s stock worth $30,000,000 after acquiring an additional 3,309 shares during the last quarter. Finally, Ranger Investment Management L.P. grew its position in Mesa Laboratories by 75.4% during the 4th quarter. Ranger Investment Management L.P. now owns 157,019 shares of the medical instruments supplier’s stock worth $32,721,000 after acquiring an additional 67,492 shares during the last quarter. Institutional investors and hedge funds own 72.57% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

See Also: Why is total return important?

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.